BriaCell Therapeutics Announces Closing of $13.8 million Public Offering
April 28 2025 - 4:05PM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care, today announced the closing of its previously announced
underwritten public offering of 3,066,666 units, including 399,999
units sold upon the full exercise of the underwriter’s option to
purchase additional units. Each unit consists of one common share
(or pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and
one warrant (the “Warrants”). Each unit was sold to the public at a
price of $4.50 per unit (inclusive of the Pre-Funded Warrant
exercise price) for gross proceeds of approximately $13.8 million,
before deducting underwriting discounts and offering expenses. The
Warrants included in the units were approved for listing on the
Nasdaq Capital Market and commenced trading under the symbol
“BCTXZ” on April 25, 2025. Each Warrant is immediately exercisable,
entitles the holder to purchase one common share at an exercise
price of $5.25 per share and expires five years from the date of
issuance. The Company is relying upon the exemption set forth in
Section 602.1 of the TSX Company Manual, which provides that the
TSX will not apply its standards to certain transactions involving
eligible interlisted issuers on a recognized exchange, such as
Nasdaq.
The Company intends to use the net proceeds from
the offering for working capital requirements, general corporate
purposes, and the advancement of business objectives.
ThinkEquity acted as the sole book-running
manager for the offering.
A registration statement on Form S-1 (File No.
333-286670) relating to the securities was filed with the
Securities and Exchange Commission (“SEC”) and became effective on
April 24, 2025, and a related registration statement was filed
pursuant to Rule 462(b) under the Securities Act of 1933, as
amended. This offering was made only by means of a prospectus.
Copies of the final prospectus may be obtained from ThinkEquity, 17
State Street, 41st Floor, New York, New York 10004. The final
prospectus has been filed with the SEC and is available on the
SEC’s website located at http://www.sec.gov.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About BriaCell Therapeutics
BriaCell is a clinical-stage biotechnology company that develops
novel immunotherapies to transform cancer care. More information is
available at https://briacell.com/.
Forward Looking StatementsThis
press release contains “forward-looking statements” that are
subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
"will” “would,” or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on the Company’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully in the section
titled “Risk Factors” in the final prospectus related to the public
offering filed with the Securities and Exchange Commission as well
as in the Company's other filings with the Canadian securities
regulatory authorities and the Securities and Exchange Commission,
all of which are available under the Company's profiles on SEDAR+
at www.sedarplus.ca and on EDGAR at
www.sec.gov. Forward-looking statements contained
in this announcement are made as of this date, and the Company
undertakes no duty to update such information except as required
under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V. Williams,
MDPresident & CEO1-888-485-6340info@briacell.com
Investor Relations
Contact:investors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Jun 2025 to Jul 2025
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Jul 2024 to Jul 2025